Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1055 first-in-human trial in malignant solid tumors
2023-507049-28-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Mar 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of GEN1055 in Non-hematologic malignancy (3 arms), sponsored by Genmab. Primary endpoints: Incidence and severity of adverse events, Incidence of dose-limiting toxicities and 1 more. Started Mar 2024; status: completed.
02
Drugs
GEN1055
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2023-507049-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507049-28-00.